Humana Inc

Most Recent

  • uploads///A doctor showing a patient a syringe used to inject testosterone
    Healthcare

    ‘Medicare for All’ Is No Reason to Drop Healthcare Stocks

    While the media caters to Millennial preferences, there’s one economic sector that’s shifting to a more seasoned crowd: healthcare stocks.

    By David Moadel
  • uploads///adult career clipboard
    Company & Industry Overviews

    This Rebate Decision Saw Health Insurers Soar Yesterday

    On Thursday, the Trump administration announced the withdrawal of the proposal to abolish rebates paid to pharmacy benefit managers by drugmakers.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    What Does Humana Expect of Its Group & Specialty Segment in 2019?

    In its first-quarter earnings press release, Humana (HUM) guided for Group & Specialty segment earnings of $300 million–$350 million.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    What Does Humana Expect of Its Medicare Business in 2019?

    In the first quarter of 2019, Humana enrolled ~30,000 members in its dual-eligible special needs plans.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Comparing Expense Trends for CNC and HUM in 2019

    In its first-quarter earnings press release, Centene (CNC) reiterated its 2019 HBR (health benefits ratio) guidance of 86.5%–87.0%.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Comparing EPS Growth Trends for CNC and HUM in 2019

    In its first-quarter earnings press release, Humana narrowed its 2019 non-GAAP EPS guidance due to the better-than-expected performance of its Retail segment.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Comparing CNC’s and HUM’s Revenue Growth Trends in 2019

    In its first-quarter earnings press release, Centene (CNC) revised its 2019 revenue guidance upward to $72.8 billion–$73.6 billion.

    By Margaret Patrick
  • uploads///medical _
    Company & Industry Overviews

    What Analysts Are Recommending for CNC and HUM in May

    Analysts’ consensus recommendations for both Centene and Humana are “buys.”

    By Margaret Patrick
  • uploads///human skeleton _
    Company & Industry Overviews

    United Health Group Stock Has Risen 28% in 2018

    On November 29, United Health Group’s (UNH) stock price closed at $282.55, which is ~8% growth from its close of $261.62 on November 23.

    By Daniel Collins
  • uploads///valuation
    Company & Industry Overviews

    How Does UNH’s Valuation Look in October?

    UnitedHealth Group is a leading managed healthcare firm in the United States.

    By Sarah Collins
  • uploads///stock price
    Earnings Report

    Analyzing UNH Stock’s Recent Performance

    On April 12, 2018, UnitedHealth Group (UNH) closed at $224.75.

    By Sarah Collins
  • uploads///BUSINESS POSITIONING
    Earnings Report

    How Is UNH’s Optum Business Positioned in the Industry?

    UnitedHealth Group is, by revenue, the largest healthcare company in the world.

    By Sarah Collins
  • uploads///medicine _
    Company & Industry Overviews

    Walmart Eyes Growth Avenues—Healthcare Could Be One

    CNBC has reported that Walmart is looking to acquire PillPack, an online pharmacy startup, for less than $1 billion.

    By Amit Singh
  • uploads///Insys priorities
    Company & Industry Overviews

    Insys Has Legal Issues Galore

    In December 2016, the U.S. Attorney’s office for the District of Massachusetts issued an indictment against six former Insys (INSY) employees.

    By Kenneth Smith
  • uploads///Chart  PFE
    Healthcare

    Inside Pfizer’s Performance in 3Q17

    PFE stock rose ~7.3% in 3Q17 and has risen ~11.3% YTD (year-to-date) as of October 16.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    Akcea Therapeutics’ Volanesorsen: 1Q17 Performance

    Volanesorsen Ionis Pharmaceuticals’s (IONS) volanesorsen is a drug designed to reduce apolipoprotein C-III production and triglycerides in patients with dyslipidemia. Akcea Therapeutics, a wholly owned subsidiary of Ionis, is engaged in pre-commercialization activities for volanesorsen, and will take care of the drug’s commercialization once it is approved by the FDA and the European Commission. The […]

    By Mike Benson
  • uploads///Graph
    Company & Industry Overviews

    Medicare Business Expected to Drive WellCare Health Plans’ Margin Growth

    In 1Q17, WellCare Health Plans’ (WCG) Medicare Health Plans business reported revenues close to $1.1 billion, which represents year-over-year growth of ~12.4%.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    WellCare Health Plans Expected to Report Solid Rise in EPS in 2017

    WellCare Health Plans has updated its earnings per share guidance from the previously estimated range of $6.00–$6.25 to the new range of $6.55–$6.80.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    WellCare Health Plans Expects Robust Revenue Performance in 2017

    In 1Q17, WellCare Health Plans (WCG) reported revenues of ~$3.9 billion, which totals year-over-year growth of around 11.7%.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Analysts’ Recommendations for WellCare Health Plans in May 2017

    On April 28, 2017, WellCare Health Plans (WCG) completed the acquisition of Universal American Corp. This deal added 119,000 Medicare Advantage members from several major markets

    By Margaret Patrick
  • uploads///Chart
    Earnings Report

    How Mylan’s North America Segment Performed

    The North America segment reported a growth of 22% to $1.6 billion during 4Q16 from $1.3 billion during 4Q15.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    Performance of Incyte’s Jakafi in the United States

    Revenues for Jakafi rose more than 42.0% to $852.8 million in 2016, from $601.0 million in 2015.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    Novartis’s Recent Developments

    Novartis (NVS) reported flat revenues at constant exchange rates during 4Q16 as well as in fiscal 2016. This was driven by growth in Sandoz revenues.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    How Did Bristol-Myers Squibb’s Oncology Segment Perform in 3Q16?

    Due to the strong performance of Opdivo, the oncology segment has emerged as the largest revenue contributor for Bristol-Myers Squibb (BMY) in 3Q16.

    By Mike Benson
  • uploads///obamacare
    Macroeconomic Analysis

    How Could Trump’s Presidency Affect Hospitals and Insurance?

    The effects of repealing Obamacare Donald Trump is definitely not in favor of the Affordable Care Act, known as Obamacare. As he wants to repeal the act completely and replace it with another policy, the hospital sector fell on November 9, the day after the election. Trump believes that providing healthcare facilities to illegal immigrants costs […]

    By Jillian Dabney
  • uploads///TLN RVS TLN basics
    Miscellaneous

    Why Is the Talen-Riverstone Spread Trading Tight?

    The merger spread is trading at 1.1% gross—about 1.9% annualized. Even in an unusually low interest rate environment, that’s a low return.

    By Brent Nyitray, CFA, MBA
  • uploads///TLN RVS downside
    Miscellaneous

    What’s the Risk-Reward Ratio for the Talen Transaction?

    If the Talen deal closes as advertised, you will make about $0.15. If the deal breaks, you will lose $1.85 per share. So, the risk-reward ratio is just over 12:1.

    By Brent Nyitray, CFA, MBA
  • uploads///TLN RVS investment thesis
    Miscellaneous

    Why Going Private Is a Good Result for Talen

    Given Talen’s close proximity to the Marcellus Shale region, it faces competition from other electricity generating companies that use cheap natural gas.

    By Brent Nyitray, CFA, MBA
  • uploads///Graph
    Earnings Report

    What Drove UnitedHealth Group’s Medicare & Retirement Business in 1Q16?

    UnitedHealthcare’s Medicare & Retirement business reported revenues worth $14.1 billion in 1Q16, which represents a YoY increase of approximately 10%.

    By Margaret Patrick
  • uploads///healthcare down biotech worse
    Macroeconomic Analysis

    Why You Should Exercise Caution When Investing in Healthcare

    The rally seen in the healthcare sector over the last five years has largely been driven by biotechnology stocks.

    By Surbhi Jain
  • uploads///Chart
    Company & Industry Overviews

    Decoding Humana’s Revenue Stream in 2015

    Humana reported revenues of about $54.3 billion in its 2015 results. This amounts to a 12% revenue growth in 2015, compared to ~$48.1 billion in 2014.

    By Mike Benson
  • uploads///ITC FTS timeline
    Miscellaneous

    ITC-Fortis Spread: What to Expect from Arbitrageurs

    The ITC (ITC)-Fortis transaction is a utility deal and arbitrageurs tend to avoid them. State regulatory approvals are generally inscrutable.

    By Brent Nyitray, CFA, MBA
  • uploads///ITC FTS downside
    Miscellaneous

    What’s the Risk-Reward Ratio for the ITC-Fortis Deal?

    ITC (ITC) was trading at ~$33 per share before the press reported it was in talks for a sale. If the deal breaks, will ITC’s share price return to its former level?

    By Brent Nyitray, CFA, MBA
  • uploads///ITC FTS strategic rationale
    Miscellaneous

    What’s the Rationale for the ITC-Fortis Merger?

    Fortis (FRTSF) is buying ITC (ITC) in the largest Canadian purchase of a US utility. Fortis intends to sell a 19% stake in order to help finance the transaction.

    By Brent Nyitray, CFA, MBA
  • uploads///ITC FRTSF spread
    Miscellaneous

    What Does the ITC-Fortis Merger Mean for Investors?

    On February 9, 2016, Fortis and ITC announced a merger. Fortis is buying ITC in a $6.6 billion deal. Including debt, the deal’s value is $11.2 billion.

    By Brent Nyitray, CFA, MBA
  • uploads///Graph
    Earnings Report

    Centene’s Specialty Services Strategy Portfolio: Backbone or Achilles Heel?

    Centene has developed a specialty services portfolio that reduces the company’s over-reliance on Medicaid and other state-sponsored businesses.

    By Margaret Patrick
  • uploads///Graph
    Earnings Report

    Managing the Revenue Expectations for Centene’s New Market Entry Strategy

    To ensure high-profit margins through 2017, Centene plans to enter new markets across its Medicaid, long-term care, and correctional health businesses.

    By Margaret Patrick
  • uploads///Graph
    Earnings Report

    Customer Growth Drove CI’s Global Supplemental Benefits Business

    In 2015, Cigna’s (CI) global supplemental benefits business earned revenues of about $3.1 billion, year-over-year (or YoY) growth of about 4.8%.

    By Margaret Patrick
  • uploads///chart
    Company & Industry Overviews

    Moving Average Trends and Analyst Estimates of JPMNX’s Top Holdings

    All of JPMNX’s top holdings except CJPXX were trading below their 20-day and 100-day moving averages as of January 29, 2016.

    By Ivan Kading
  • uploads///chart
    Company & Industry Overviews

    Running down JPMNX: Structural Analysis of an Alternative Mutual Fund

    JPMNX is an alternative mutual fund that seeks to mimic the “market neutral” hedge fund strategy in achieving its investment objectives.

    By Ivan Kading
  • uploads///Graph
    Earnings Report

    Anthem Expects to Generate Substantial Savings from Pharmaceutical Pricing in 2016

    Anthem plans to negotiate pharmaceutical pricing with Express Scripts in an effort to improve affordability, secure more members, and enroll new customers.

    By Margaret Patrick
  • uploads///Graph
    Earnings Report

    Government-Sponsored Programs Expected to Drive Aetna’s Revenue

    Government-sponsored programs such as Medicare and Medicaid are expected to be key drivers of Aetna’s (AET) revenue growth in 4Q15.

    By Margaret Patrick
  • uploads///Graph Part  Nov
    Company & Industry Overviews

    UnitedHealth Declares Dividend, Stock Rises

    UnitedHealth Group rose 1.4% on November 10, 2015. The company announced a dividend of $0.5 per share to be paid on December 15, 2015.

    By Peter Neil
  • uploads///cnc pm
    Earnings Report

    Centene’s Revenue and Income Rose in 3Q15

    Centene has reported net revenue of $5,821 million in 3Q15, an increase of 5.7% compared to $5,506 million in 2Q15. Operating revenue increased 5.8% in 3Q15.

    By Gabriel Kane
  • uploads///Graph
    Earnings Report

    UnitedHealth Group’s 3Q15 Medical Care Ratio Rose

    In 3Q15, UnitedHealth Group’s consolidated medical care ratio, which is the ratio of medical costs to the premium revenue, fell by 0.9% on a year-over-year (or YoY) basis.

    By Margaret Patrick
  • uploads///Graph
    Earnings Report

    What Are UnitedHealth Group’s Growth Opportunities?

    To strengthen their presence in international markets, health insurance companies have been involved in mergers and acquisitions with local insurance companies in these markets.

    By Margaret Patrick
  • uploads///Graph
    Earnings Report

    UnitedHealthcare Added 1.7 Million Enrollments in 3Q15

    In 3Q15, UnitedHealth Group’s (UNH) UnitedHealthcare segment added 1.7 million people year-over-year across the commercial, Medicare, and Medicaid benefits markets in the US.

    By Margaret Patrick
  • uploads///Graph
    Earnings Report

    Reduced Expenses Lead to Aetna’s Higher 1Q15 Margins

    Aetna’s EBITDA margins rose from 10.6% in 1Q14 to 11.3% in 1Q15. Enrollment growth and an effective cost optimization strategy led to the high margins.

    By Margaret Patrick
  • uploads///Graph Part
    Company & Industry Overviews

    Humana Stock Rose 4.34% August 25–31

    With a market cap of $27 billion, Humana is one of the leading companies in the healthcare service subgroup. HUM stock rose 4.34% for the period August 25–31, 2015.

    By Peter Neil
  • uploads///CI ANTM EPS accretion
    Miscellaneous

    Is the Cigna–Anthem Merger a Setup?

    The Cigna–Anthem merger deal will be subject to all sorts of headlines that will affect the spread. You can make a decent return trading around the position by keeping your head .

    By Brent Nyitray, CFA, MBA
  • uploads///CI ANTM downside
    Miscellaneous

    The Risk-to-Reward Ratio of the Cigna–Anthem Merger

    If the Cigna–Anthem merger closes, you end up making about $35 a share. If the deal breaks, then you would have to cover at $52 a share.

    By Brent Nyitray, CFA, MBA
  • uploads///CI ANTM spread
    Miscellaneous

    The Huge Spread on the Cigna–Anthem Merger

    In the case of the Cigna–Anthem merger, Anthem (ANTM) is buying Cigna (CI) for a headline amount of $188 a share, comprised of 0.5152 shares of Anthem and $103.40 in cash.

    By Brent Nyitray, CFA, MBA
  • uploads///Graph
    Miscellaneous

    Synergies in Centene’s Acquisition of Health Net

    Centene projects that Health Net’s acquisition will help Centene realize pre-tax synergies worth $150 million by the end of the second year after the closure of the deal.

    By Margaret Patrick
  • uploads///Graph
    Miscellaneous

    Centene Announces Its Acquisition of Health Net

    On July 2, Centene announced the acquisition of Health Net for a combination of cash and shares amounting to $6.8 billion. This includes the assumption of Health Net’s $500 million debt.

    By Margaret Patrick
  • uploads///HUM AET downside
    Miscellaneous

    What Is the Risk-to-Reward Ratio of the Humana–Aetna Deal?

    Scenario analysis  In the risk-arbitrage world, a 12.2% expected return means a deal that has a lot of risk. Arbitrageurs sometimes refer to risk as “hair.” This deal is guaranteed a second request, and the regulators may simply be unable to get comfortable with the transaction, no matter what the companies offer in the way […]

    By Brent Nyitray, CFA, MBA
  • uploads///HUM AET comps
    Miscellaneous

    Could Competing Bids Disrupt Aetna’s Purchase of Humana?

    Aetna is buying Humana for about $37 billion, which works out to be about 0.73x trailing 12-month revenues and 13.7x trailing 12-month EBITDA.

    By Brent Nyitray, CFA, MBA
  • uploads///Graph
    Miscellaneous

    The Aetna-Humana Deal: Must-Know Risks to Consider

    On July 3, 2015, Aetna announced the acquisition of its peer, Humana (HUM), for a consideration of $37 billion.

    By Margaret Patrick
  • uploads///CI ANTM EPS accretion
    Miscellaneous

    Rationale for the Cigna-Anthem Transaction

    The merger of Anthem and Cigna is all about extracting synergies and driving down costs. As the Affordable Care Act puts pressure on health insurers, they need to cut costs to maintain margins.

    By Brent Nyitray, CFA, MBA
  • uploads///Graph
    Earnings Report

    Humana’s Commercial Enrollments Face Pressure in 1Q15

    Humana’s (HUM) revenues from commercial enrollments increased by 28.4%, from $2.2 billion in 1Q14 to $2.8 billion in 1Q15.

    By Margaret Patrick
  • uploads///Graph
    Earnings Report

    Key Takeaways from Centene’s 1Q15 Earnings Release

    Centene (CNC) posted its 1Q15 earnings on April 28, 2015. The company beat the Wall Street diluted EPS estimates of $0.49 with a posted EPS of $0.52.

    By Margaret Patrick
  • uploads///Market Reaction on FOMC Statement April
    Macroeconomic Analysis

    Should Markets Be Happy or Worried about April FOMC Statement?

    Should the markets be happy about a later-than-expected rate hike? Or should they be worried that the FOMC’s optimism may spell the end of their golden run?

    By David Ashworth
  • uploads///Graph
    Earnings Report

    Key Takeaways from Aetna’s 1Q15 Earnings Release

    Aetna (AET) announced its 1Q15 earnings on April 28, 2015. The company posted EPS of $2.30, beating Wall Street EPS estimates of $1.94.

    By Margaret Patrick
  • uploads///Graph
    Earnings Report

    Cigna’s Shares Up by 16.4% Since Its Previous Earnings Release

    Cigna’s revenue is estimated to be $9.3 billion, and its EBITDA margin is expected to be ~9.0%. Its net income is expected to be around $480.6 million.

    By Margaret Patrick
  • uploads///Graph
    Earnings Report

    Medicare Advantage Enrollments Drive Humana’s 1Q15 Revenue Growth

    The total Medicare Advantage beneficiaries in the US rose by 1.3 million, from 16.1 million in 1Q14 to 17.4 million in 1Q15.

    By Margaret Patrick
  • uploads///Graph
    Earnings Report

    Aetna’s 1Q15 Revenue: Driven by Government-Sponsored Enrollments

    The rise in Aetna’s EPS is mainly attributed to the increase in the company’s government-sponsored MA (Medicare Advantage) and Medicaid enrollments in 1Q15.

    By Margaret Patrick
  • uploads///Graph
    Earnings Report

    UnitedHealth Group Valuation Continues Uptrend on 1Q15 Earnings

    UnitedHealth Group is acquiring Catamaran for a consideration of $12.8 billion. Increasing debt may reduce future net earnings and could affect the company’s valuation.

    By Margaret Patrick
  • uploads///Graph
    Earnings Report

    UnitedHealth Group’s Optum Posts Healthy 1Q15 Operating Earnings

    The Optum segment offers pharmacy, quality management, and health technology services. Operating earnings grew by 14% year-over-year to $742 million.

    By Margaret Patrick
  • uploads///Graph
    Earnings Report

    Key Takeaways from UnitedHealth Group 1Q15 Earnings

    UnitedHealth Group (UNH) posted its 1Q15 earnings on April 16, 2015. Following the release, UnitedHealth Group’s share price increased by 3.6%.

    By Margaret Patrick
  • uploads///HUM
    Fund Managers

    Corvex Exits Stake in Humana

    In the fourth quarter of 2014, Humana reported revenue of $12.3 billion, up 21% year-over-year. Of this total, $8.65 billion came from the MA program.

    By Samantha Nielson
  • uploads///Graph
    Company & Industry Overviews

    Medical Care Ratio – Centene Compared to Its Peers

    For health insurance companies, the medical care ratio is the ratio of total money spent on healthcare claims to premiums earned—adjusted for tax and regulatory expenses.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Specialty Services: How Does Centene Manage Them?

    Aside from the standard healthcare policies, players—like Centene—in the private health insurance industry (IYH) also offer specialty insurance.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Centene: Insurance Exchange Opportunity and Hybrid Plans

    In 2014, Centene entered into a contract with Arkansas to participate in a hybrid Medicaid program. The program is expected to expire in December 2015.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    What Are Centene’s Key Business Segments?

    Centene operates local health plans. Its Managed Care segment offers health insurance services to individuals through government-subsidized programs.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Anthem: Managing Government-Sponsored Health Insurance

    Anthem’s government-sponsored enrollments include Medicaid, Medicare, and Federal Employee Program plan members.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Anthem’s Suite of Pharmacy Services

    Manufacturer discounts and rebates are a major source of pharmacy benefit management business revenue.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Anthem Valuation Under Pressure

    Anthem’s valuation remains subdued mainly because it has fewer government-sponsored enrollments and higher financial leverage.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Anthem’s Key Business Segments

    In 2014, of Anthem’s three business segments, Commercial and Specialty accounted for 53.7% of total revenues, and Government Business contributed 46.3%.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Anthem’s Membership Mainly Local Employers

    Anthem’s membership is mainly concentrated in the local group, total national, and Medicaid population. The local group accounts for about 40.4% of members.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Anthem’s Medical Care Ratio Improves, Boosts Profit Margin

    Anthem’s medical care ratio declined from 87.8% in 2013 to 83.1% in 2014, as a result of its favorable enrollment mix.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Anthem Shifts to a Value-Based Payment Model

    Anthem (ANTM) has value-based payment contracts with 33,000 primary care physicians, which implicates over 3 million members.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Anthem: Mergers and Acquisitions Target Medicaid, Medicare

    Anthem’s mergers and acquisitions strategy mainly targets the company’s government-sponsored business.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Anthem: One of America’s Largest Health Insurance Providers

    Anthem provides health benefits and services to about 69 million people through its affiliated companies. It came 38th in the 2014 Fortune 500 rankings.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Cigna’s Customer Segments a Healthy Mix

    Customer segments The players in the private health insurance industry (IYH) aim for a favorable enrollment mix to reduce taxes and other liabilities while at the same time generating sustainable profits. Accordingly, managed care organizations such as Humana (HUM), Aetna (AET), Anthem, Cigna (CI), and WellCare Health Plans (WCG) are increasingly focusing on government-sponsored and international enrollments to balance […]

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Cigna’s Medical Care Ratio Ticks Upward

    Cigna’s medical care ratio concerned with the company’s Medicare prescription drug enrollments increased from 82.3% in 2013 to 86.3% in 2014.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Cigna’s Main Business Risks

    Cigna (CI) faces a unique combination of business risks as well as industry-specific risks. Business diversification is key to mitigating such risks.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Cigna Controls Risk-Based Capital Requirements

    The Cigna business model is more concentrated toward commercial enrollments but is diversified across various delivery platforms.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Cigna: Medicare and Medicaid Beneficiaries Top Earners

    Most of Cigna’s revenue comes from insurance for employer-sponsored as well as Medicare and Medicaid beneficiaries.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Cigna Increases Dental Specialty Health Insurance Premiums

    Health insurance companies (IYH) provide specialty insurance services through managed care offerings such as health maintenance organizations.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Cigna: Global Supplemental Benefits Earn 9% of Revenues

    Cigna’s (CI) Global Supplemental Benefits segment accounts for about 9% of the company’s total revenues.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Cigna: International Expansion Key to Growth Strategy

    International expansion is a hallmark of Cigna’s business. Cigna has inked deals in Turkey, Belgium, Brazil, Japan, Taiwan, Thailand, et cetera.

    By Margaret Patrick
  • uploads///Graph
    Earnings Report

    Aetna’s Valuation Compared to Its Peers

    Aetna’s valuations were lower than its peers in 4Q14. With Aetna investing in growth initiatives, the valuations are expected to rise in 2015.

    By Margaret Patrick
  • uploads///Graph
    Earnings Report

    Aetna’s Pharmacy Business Faced Challenges in 2014

    Aetna narrowed its pharmacy network to employ higher drug discounts to the contracted pharmacies in exchange of dedicated patient volumes.

    By Margaret Patrick
  • uploads///Graph
    Earnings Report

    Star Ratings Increased Aetna’s Government-Sponsored Business in 4Q14

    Aetna (AET) earns about 38% of its revenue by providing health insurance services to government-sponsored enrollees.

    By Margaret Patrick
  • uploads///Graph
    Earnings Report

    Aetna Reported Revenue Growth in Its 4Q14 Earnings

    On February 3, 2015, Aetna reported its 4Q14 financial results. The company reported revenue of $14.7 billion in 4Q14—an increase of 12.1% YoY.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Why Aetna Is Shifting to a Value-Based Payment Model

    Aetna projects that its value-based spending as a part of the total spending will rise from 25% in 2014 to 50% in 2018.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    How Does Aetna Make Payments to Its Provider Network?

    Managed care organizations (XLV) enter into a contract with a set of health care providers, or a provider network, to provide care for members at reduced costs.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Aetna’s Strategy for Its Specialty Insurance Business

    Aside from the standard healthcare policies, players in the private health insurance industry also offer specialty insurance.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    What Is Aetna’s Strategy for Its Individual Insurance Business?

    Reforms in the individual insurance segment have created an opportunity for the private health insurance industry (XLV) to attract new enrollments.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    How Does Aetna Manage Its Commercial Business?

    Aetna (AET) derives 58% of its operating revenues from its commercial business, which involves offerings such as fully insured health plans and self-insured health plans.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    How Is Aetna’s Membership Distributed Across Its Key Markets?

    Aetna’s membership is mainly concentrated in the western US, followed by the Southeast, the Northeast, the Mid-US, and finally consolidated international enrollments.

    By Margaret Patrick
    • CONNECT with Market Realist
    • Link to Facebook
    • Link to Twitter
    • Link to Instagram
    • Link to Email Subscribe
    Market Realist Logo
    Do Not Sell My Personal Information

    © Copyright 2021 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.